Media Gallery

It has proven that anti-microbial properties with a direct virucidal effect on SARS-CoV-2. NONS, when sprayed over nasal mucosa, acts as a barrier against the virus, preventing it from incubating and spreading to the lungs

Chinese Foreign Ministry spokesman Zhao Lijian said that Beijing wants an orderly return of the students as per the safety protocols of Covid-19.

The Mumbai-based pharmaceutical company received manufacturing-marketing approval from India’s drug regulator, Drugs Controller General of India (DCGI) for Nitric Oxide Nasal Spray as part of an accelerated approval process.

First nasal spray for covid-19 treatment in India: FabiSpray, Nitric Oxide Nasal Spray (NONS), according to Glenmark, is designed to kill the COVID-19 virus in the upper airways. (ANI)

देश में कोरोना मरीजों की संख्या अब धीरे-धीरे कम हो रही है. वहीं अब कोरोना मरीजों के लिए बड़ी खुशखबरी आई है. अब उनका इलाज सूई-दवाई से ही नहीं अब नेजल स्प्रे से भी होगा. भारत में लॉन्च हुआ FabiSpray कोरोना के इलाज में और इसे रोकने में काफी कारगर साबित हुआ है. जानिए पूरी डिटेल्स

FabiSpray, Nitric Oxide Nasal Spray, is designed to kill the COVID-19 virus in the upper airways.

FabiSpray is a Nitric Oxide Nasal Spray (NONS) designed to kill the COVID-19 virus in the upper airways. It has proven anti-microbial properties with a direct virucidal effect on SARS-CoV-2.

New Delhi: Glenmark launched Nitric Oxide Nasal Spray (FabiSpray) in India in partnership with SaNOtize for treating adult patients infected with COVID-19.

New Delhi [India]: Mumbai based innovation-driven global pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult patients suffering from COVID-19.

Glenmark Pharmaceuticals and its partner Canadian biotech firm SaNOtize Research on Wednesday launched Nitric Oxide nasal spray for the treatment of adult patients with COVID-19, who have a high risk of progression of the disease.

Mumbai based innovation-driven global pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult patients suffering from Covid-19.

Mumbai based innovation-driven global pharma company Glenmark has launched Nitric Oxide Nasal Spray (FabiSpray) in India, in partnership with SaNOtize, for treatment of adult patients suffering from Covid-19.

Glenmark Pharmaceuticals and its partner Canadian biotech firm SaNOtize Research on Wednesday launched Nitric Oxide nasal spray for the treatment of adult patients with COVID-19, who have a high risk of progression of the disease. The partners have introduced the product in India under the brand name FabiSpray.

Glenmark Pharmaceuticals and its partner Canadian biotech firm SaNOtize Research on Wednesday launched Nitric Oxide nasal spray for the treatment of adult patients with COVID-19, who have a high risk of progression of the disease.

Glenmark received manufacturing and marketing approval from India’s drug regulator, Drugs Controller General of India, for Nitric Oxide Nasal Spray as part of the accelerated approval process.

Coronavirus Omicron India Highlights | This takes the total confirmed coronavirus cases in the country to 4,24, 10, 976. Of the new cases, Kerala reported the highest 29,471 new cases followed by Maharashtra (6,107) and Tamil Nadu (4,519).

On Wednesday, Glenmark Pharmaceuticals launched a nasal spray for the treatment of Covid-19 in high-risk adult patients in India.

The company stated that it has proven anti-microbial properties with a direct virucidal effect on SARS-CoV-2.

Glenmark Pharmaceuticals’ share price rose 2 percent in the morning trade on February 9 after the company announced the launch of nitric oxide nasal spray (NONS) in India for COVID-19 patients.

Glenmark received approval for marketing and manufacturing from the Drugs Controller General of India (DCGI) for NONS as part of its accelerated approval process.

Glenmark Pharmaceuticals and its partner Canadian biotech firm SaNOtize Research on Wednesday launched Nitric Oxide nasal spray for the treatment of adult patients with COVID-19, who have a high risk of progression of the disease.

#JustIn | Glenmark introduces COVID-19 treatment Nitric Oxide Nasal Spray (NONS)

Glenmark Pharmaceuticals rose 1.90% to Rs 494.25 after the company launched Nitric Oxide Nasal Spray (FabiSpray) in India for the treatment of adult patients with COVID-19.

FabiSpray is a Nitric Oxide Nasal Spray (NONS) designed to kill the COVID-19 virus in the upper airways. It has proven anti-microbial properties with a direct virucidal effect on SARS-CoV-2.

Glenmark launches Nitric Oxide Nasal Spray(FabiSpray®)in India for treatment of adult patients with #COVID19,in partnership with SaNOtize.

‘फैबीस्प्रे’ से कोरोना के उन मरीजों का उपचार किया जाएगा, जिनमें महामारी तेजी से बढ़ने का अंदेशा होगा।

Coronavirus LIVE: Keep refreshing this space for all the accurate COVID-19 related news.

India logged 71,365 new coronavirus infections taking the country’s total tally of COVID-19 cases to 4,24,10,976, while the active cases declined to 8,92,828, according to the Union Health Ministry data updated on Wednesday.

Indian pharma major Glenmark Pharmaceuticals Limited and Canadian pharmaceutical company SaNOtize Research & Development Corp, on Wednesday announced launch of nasal spray to treat adult Covid-19 patients.

Has proven anti-microbial properties with a direct virucidal effect on SARS-CoV-2, Glenmark

Glenmark Pharmaceuticals Ltd’s Chief Commercial Officer Robert Crockart said “we are confident it will offer patients a much needed and timely therapy option.”

Glenmark Pharmaceuticals Limited (Glenmark) has launched Nitric Oxide Nasal Spray, under the brand name FabiSpray for the treatment of adult COVID patients.

As the third coronavirus wave in India shows a downward trend, India on Wednesday, 9 February, reported 71,365 new COVID-19 cases and 1,217 deaths.

Glenmark claims that when the Nitric Oxide Nasal is sprayed over nasal mucosa it acts as a physical and chemical barrier against the virus.

In a major development in the COVID-19 medicine field, Glenmark Pharmaceuticals on Wednesday launched its Nitric Oxide Nasal Spray under the brand name FabiSpray in India.

Glenmark Pharmaceuticals Limited (Glenmark) and Canadian pharmaceutical company SaNOtize Research & Development Corp. today announced the launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India for the treatment of adult patients with COVID-19 who have high risk of progression of the disease.

Indian pharma major Glenmark Pharmaceuticals Limited and Canadian pharmaceutical company SaNOtize Research & Development Corp, on Wednesday announced launch of nasal spray to treat adult Covid-19 patients.

While India has received its first nasal spray, FabiSpray for the treatment of Coronavirus, there are several speculations over its effectiveness

New Delhi, Feb 9 (PTI) Glenmark Pharmaceuticals and its partner Canadian biotech firm SaNOtize Research on Wednesday launched Nitric Oxide nasal spray for the treatment of adult patients with COVID-19, who have a high risk of progression of the disease.

The Mumbai-based pharmaceutical company received manufacturing-marketing approval from India’s drug regulator, Drugs Controller General of India (DCGI) for Nitric Oxide Nasal Spray as part of an accelerated approval process.

FabiSpray is designed to kill the COVID-19 virus in the upper airways, and has proven anti-microbial properties with a direct virucidal effect on SARS-CoV-2, the companies said in a press statement.

FabiSpray has to be taken based on prescription by and discretion of a registered medical practitioner. “The pricing of Fabispray is nominal in India compared to other countries,” said Dr. Monika Tandon, head, clinical development at Glenmark.

FabiSpray is used for treating adult COVID-19 patients who are at high risk of progression of the disease.Mumbai-headquarted pharmaceutical company Glenmark Pharmaceuticals has rolled out India’s first Nitric Oxide Nasal Spray (NONS) named FabiSpray in collaboration with Canadian pharmaceutical company SaNOtize Research and Development Corporation.

Mumbai (Maharashtra) [India], February 9 (ANI/PRNewswire): Glenmark Pharmaceuticals Limited (Glenmark) – a global, innovation-driven pharmaceutical company and Canadian pharmaceutical company SaNOtize Research & Development Corp.

FabiSpray is a Nitric Oxide Nasal Spray (NONS) designed to kill the COVID-19 virus in the upper airways. It has proven anti-microbial properties with a direct virucidal effect on SARS-CoV-2.

Glenmark claims that when the Nitric Oxide Nasal is sprayed over nasal mucosa it acts as a physical and chemical barrier against the virus.

The Mumbai-based drug firm had earlier received manufacturing and marketing approval from the Drugs Controller General of India (DCGI) for the Nitric Oxide nasal spray (NONS) as part of the accelerated approval process

Glenmark Pharmaceuticals Limited (Glenmark) has launched Nitric Oxide Nasal Spray, under the brand name FabiSpray for the treatment of adult COVID patients.

Glenmark Pharmaceuticals and Canadian pharmaceutical company SaNOtize Research & Development Corp have launched its nitric oxide nasal spray (NONS) under the brand name FabiSpray in India.

Glenmark Pharmaceuticals and Canada-based SaNOtize Research & Development have introduced the Nitric Oxide Nasal Spray (NONS) to treat Covid-19 in adult patients in India.